Associated Genetic Biomarkers
NCI Definition: An aggressive malignant neoplasm with a poor response to therapy, usually presenting as stage III/IV disease. It is characterized by the presence of neoplastic cells with morphologic and immunophenotypic characteristics similar to those seen in mature histiocytes. 
There are 3 clinical trials for histiocytic sarcoma, of which 3 are open and 0 are completed or closed. Of the trials that contain histiocytic sarcoma as an inclusion criterion, 3 are phase 2 (3 open).
BRAF is the most frequent gene inclusion criterion for histiocytic sarcoma clinical trials .
Cobimetinib, pembrolizumab, and vemurafenib are the most common interventions in histiocytic sarcoma clinical trials.
Significant Genes in Histiocytic Sarcoma
BRAF is an inclusion eligibility criterion in 1 clinical trial for histiocytic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and histiocytic sarcoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.